Story

SK Biopharmaceuticals to Acquire Epilepsy Drug Portfolio from Biohaven for Up to $795 Million

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20261 min read
SK Biopharmaceuticals to Acquire Epilepsy Drug Portfolio from Biohaven for Up to $795 Million
Text size
Background

SK Biopharmaceuticals has entered into a worldwide licensing agreement with Biohaven Bioscience Ireland to acquire rights to a portfolio of epilepsy treatments, including the drug candidate Opakalim. The deal, which could be worth up to $795 million, significantly expands SK Biopharmaceuticals' pipeline in the neurology sector.

Deal Structure and Financials

Under the terms of the agreement, SK Biopharmaceuticals will make an upfront payment of $400 million, according to a company filing on Wednesday. The initial payment is structured in two tranches:

  • $350 million due upon the closing of the transaction.
  • An additional $50 million to be paid one year after closing.

Beyond the upfront cash, the agreement includes potential milestone payments that bring the total value to $795 million. Biohaven is also set to receive tiered royalties based on future net sales of any commercialized products from the licensed assets.

Strategic Implications

Sample IUX Markets – In-articleAd

The acquisition provides SK Biopharmaceuticals with the rights to Opakalim and other compounds based on Kv7 activator technology. This deal also includes Biohaven's Kv7 discovery platform, giving the company broader capabilities for developing future treatments for epilepsy and other neurological disorders.

For Biohaven, the transaction monetizes a key part of its research and development pipeline, providing a substantial infusion of non-dilutive capital. The royalty structure ensures it will continue to benefit from the long-term commercial success of the assets it originally developed.

Market Reaction

Investors on both sides responded positively to the announcement. In stock market trading, shares of Biohaven (NYSE: BHVN) rose 5.12%, while SK Biopharmaceuticals (KRX: 326030) saw its shares climb 8.89%. The market reaction suggests that investors view the deal as strategically sound and financially beneficial for both companies, signaling confidence in the potential of the licensed drug platform.

Read next

More on Stocks
Back to latest news

LATEST